RARE-02. OBSERVATIONAL REGISTRY STUDY OF TREATMENT PRACTICES AND LONG-TERM OUTCOMES OF CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND PLEXIFORM NEUROFIBROMAS (PN) INITIATING SELUMETINIB IN REAL-WORLD PRACTICE IN THE UNITED STATES (US): STUDY DESIGN AND METHODOLOGY

Selumetinib (ARRY-142886, AZD6244) is an oral, allosteric MEK1/2 inhibitor approved in the US for children aged ≥2 years with NF1 and symptomatic, inoperable PN, based on results from the pivotal SPRINT study. Aims of the US Selumetinib Registry study [NCT05683678] include understanding treatment pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Waanders, Angela, Yohay, Kaleb, Fang, Shona, Wahlstrom, Svea, Bornhorst, Miriam, Meade, Julia, Vallance, Kelly, Rodriguez, Randolph de la Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Final Category: Germ Cell Tumors/Rare Tumors - RARE
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259971/
http://dx.doi.org/10.1093/neuonc/noad073.131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259971/
http://dx.doi.org/10.1093/neuonc/noad073.131

Ejemplares similares